Ronda Stryker - Stryker Independent Director
SYK Stock | USD 357.87 0.84 0.23% |
Director
Ms. Ronda E. Stryker is Independent Director of Stryker Corporationration She is a Granddaughter of the founder of the Company and daughter of a former President of the Company. She is also Vice Chair and a director of Greenleaf Trust, a Michigan chartered bank, Vice Chair of Spelman College and member of the Harvard Medical School Board of Fellows. Ms. Stryker brings a strong interest in advocating the benefits of diversity and various matters regarding social responsibility. As the Company largest individual shareholder and a member of the founding family, she brings a strong shareholder perspective, unlike that of any other member of our Board, making her a valuable component of a wellrounded Board. since 1984.
Age | 66 |
Tenure | 40 years |
Address | 1941 Stryker Way, Portage, MI, United States, 49002 |
Phone | 269 385 2600 |
Web | https://www.stryker.com |
Stryker Management Efficiency
The company has Return on Asset of 0.0687 % which means that on every $100 spent on assets, it made $0.0687 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1798 %, implying that it generated $0.1798 on every 100 dollars invested. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is expected to rise to 0.21 this year. Return On Assets is expected to rise to 0.11 this year. At this time, Stryker's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 41.9 B this year, although the value of Non Current Liabilities Other will most likely fall to about 1.8 B.Similar Executives
Showing other executives | DIRECTOR Age | ||
Yair Rabinovitch | Medigus Ltd ADR | 67 | |
Gary Pruden | Motus GI Holdings | 56 | |
Oded Yatzkan | Medigus Ltd ADR | 49 | |
Aviel Shapira | Medigus Ltd ADR | 61 | |
Yuval Yanai | Medigus Ltd ADR | 65 | |
Gary Jacobs | Motus GI Holdings | 59 | |
Shervin Korangy | Motus GI Holdings | 43 | |
Darren Sherman | Motus GI Holdings | 45 | |
Ori Hershkovitz | Medigus Ltd ADR | 39 | |
Doron Birger | Medigus Ltd ADR | 66 | |
Efrat Venkert | Medigus Ltd ADR | 46 | |
Yair Rabinowitch | Medigus Ltd ADR | 71 | |
Samuel Nussbaum | Motus GI Holdings | 69 | |
Jeremy Starkweather | Medigus Ltd ADR | 42 | |
Anat Naschitz | Medigus Ltd ADR | N/A | |
Eitan Machover | Medigus Ltd ADR | 55 | |
Erez Haimovitz | Medigus Ltd ADR | N/A |
Management Performance
Return On Equity | 0.18 | ||||
Return On Asset | 0.0687 |
Stryker Leadership Team
Elected by the shareholders, the Stryker's board of directors comprises two types of representatives: Stryker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stryker. The board's role is to monitor Stryker's management team and ensure that shareholders' interests are well served. Stryker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stryker's outside directors are responsible for providing unbiased perspectives on the board's policies.
Andrew Silvernail, Independent Director | ||
Fink, Vice President Global Human Resources | ||
Sherilyn McCoy, Independent Director | ||
Lisa Tatum, Independent Director | ||
Robert Cohen, CTO Replacement | ||
Ronda Stryker, Independent Director | ||
Preston Wells, Vice President - Investor Relations | ||
Curtis Hall, Chief Legal Officer | ||
Ramesh Subrahmanian, Advisor | ||
Spencer Stiles, Group President Orthopaedics and Spine | ||
Andrew Pierce, Group Neurotechnology | ||
William Berry, Principal Accounting Officer, Vice President, Corporate Controller | ||
Allan Golston, Lead Independent Director | ||
Katherine Owen, Vice President - Strategy and Investor Relations | ||
Graham Mclean, President Asia-Pacific | ||
Louise Francesconi, Independent Director | ||
Kevin Lobo, Chairman of the Board, President, Chief Executive Officer | ||
Giovanni Caforio, Independent Director | ||
Jason Beach, Vice Relations | ||
Roch Doliveux, Independent Director | ||
David Floyd, Group President of Orthopaedics | ||
William Jellison, CFO and VP | ||
Yin Becker, Vice President - Communications, Public Affairs and Corporate Marketing | ||
M Fink, Chief Human Resource Officer, Vice President | ||
Timothy Scannell, Group President of Medsurg and Neurotechnology | ||
William Parfet, Non-Executive Independent Chairman of the Board | ||
Robert Fletcher, Vice President Chief Legal Officer | ||
Dean Bergy, VP and Corporate Secretary | ||
Rajeev Suri, Independent Director | ||
Alan Douville, Chief VP | ||
Glenn Boehnlein, Chief Financial Officer, Vice President | ||
J Pierce, Group President MedSurg and Neurotechnology | ||
Viju Menon, Group President - Global Quality and Business Operations | ||
Lonny Carpenter, Group President - Global Quality and Operations | ||
Bijoy Sagar, Chief Digital Technology Officer, Vice President | ||
Mary Brainerd, Independent Director | ||
Srikant Datar, Independent Director | ||
Michael Hutchinson, General Counsel | ||
Bronwen Taylor, Vice President - Compliance and Risk Management | ||
Howard Cox, Independent Director | ||
Steven Benscoter, Vice President - Human Resources | ||
Kathryn Fink, Chief Human Resource Officer, Vice President | ||
Scott Bruder, Vice President Chief Medical and Scientific Officer |
Stryker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stryker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.18 | ||||
Return On Asset | 0.0687 | ||||
Profit Margin | 0.15 % | ||||
Operating Margin | 0.24 % | ||||
Current Valuation | 146.35 B | ||||
Shares Outstanding | 380.26 M | ||||
Shares Owned By Insiders | 5.39 % | ||||
Shares Owned By Institutions | 78.75 % | ||||
Number Of Shares Shorted | 3.8 M | ||||
Price To Earning | 63.07 X |
Currently Active Assets on Macroaxis
When determining whether Stryker is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stryker Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stryker Stock. Highlighted below are key reports to facilitate an investment decision about Stryker Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stryker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Stryker Stock please use our How to buy in Stryker Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Stryker Stock analysis
When running Stryker's price analysis, check to measure Stryker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stryker is operating at the current time. Most of Stryker's value examination focuses on studying past and present price action to predict the probability of Stryker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stryker's price. Additionally, you may evaluate how the addition of Stryker to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Stryker's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stryker. If investors know Stryker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stryker listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.027 | Dividend Share 3.05 | Earnings Share 8.25 | Revenue Per Share 53.999 | Quarterly Revenue Growth 0.118 |
The market value of Stryker is measured differently than its book value, which is the value of Stryker that is recorded on the company's balance sheet. Investors also form their own opinion of Stryker's value that differs from its market value or its book value, called intrinsic value, which is Stryker's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stryker's market value can be influenced by many factors that don't directly affect Stryker's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stryker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Stryker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stryker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.